The total number of records retrieved from this search are 11. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_2232	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineSK-BR-3	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.01 MOI	In-vitro result90% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_2233	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineSK-BR-3	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.01 MOI	In-vitro result60% cell survival after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_2234	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineSK-BR-3	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.01 MOI	In-vitro result55% cell survival after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_2235	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineSK-BR-3	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.01 MOI	In-vitro result40% cell survival after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_2236	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineSK-BR-3	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell death after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_2237	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineSK-BR-3	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.1 MOI	In-vitro result60% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_2238	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineSK-BR-3	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.1 MOI	In-vitro result40% cell survival after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_2239	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineSK-BR-3	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.1 MOI	In-vitro result20% cell survival after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_2240	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineSK-BR-3	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.1 MOI	In-vitro result10% cell survival after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_2241	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineSK-BR-3	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell death after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_4320	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast adenocarcinoma	Cell lineSK-BR-3	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 pfu	In-vitro result89.6 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347